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Chromosomal damage in peripheral
blood lymphocytes from nurses
occupationally exposed to chemicals
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Abstract
In the present study, we evaluated the induced genome damage in peripheral blood lymphocytes from a sample
of nurses occupationally exposed to low doses of different chemicals. A comprehensive multi-biomarker
approach using cytogenetic endpoints was employed for analyzing chromosomal aberrations (CAs) and sis-
ter chromatid exchange (SCE) assay. The study included 20 nurses and 20 control subjects matched in age,
gender and smoking habits. Nurses were exposed to different chemicals, such as cytostatic drugs, anaes-
thetics, formaldehyde and other sterilizing gases. Significant differences were found between exposure group
and control group in terms of SCEs frequency (p < 0.001) but not in terms of replication index value (p¼ 0.845)
and CAs (p ¼ 0.236). Regression analyses indicated that the age and the exposure years did not influence the
amount of the chromosomal damage among nurses. Vice versa, among controls, a positive correlation was found
between the number of SCEs and age. In conclusion, our results suggest that a continuous long-term exposure to
low doses of chemicals could result in increased levels of SCEs among nurses. This data emphasize the impor-
tance of biomonitoring nurses and other hospital workers handling drugs.
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Introduction
At the workplace, nurses are exposed to a wide spec-
trum of different drugs in sub-therapeutic concentra-
tions, with unknown biological consequences. In
general, occupational exposure to cytostatic drugs,
anaesthetic and sterilizing gases with potential muta-
genic and carcinogenic capacity is a major hazard for
the health care personnel.
For example, ethylene oxide and formaldehyde,
used for sterilization, are well-known human carcino-
gens and are related to an increase of both chromoso-
mal aberrations (CAs) and sister chromatid exchanges
(SCEs) among exposed subjects.1,2 Moreover, some
of antineoplastic drugs (including alkylating agents,
antimetabolites, antibiotics and hormones) used for
the treatment of various types of cancer and immuno-
logic diseases have been classified to be carcinogenic
to humans according to their mutagenic and clasto-
genic properties.3,4
It is known that formaldehyde and antineoplastic
drugs induce reactive oxygen species (ROS) that can
cause DNA strand breaks, alteration in bases and
chromosomal rearrangements. Moreover, ROS can
affect cell function by acting directly not only on
DNA but also on lipids and proteins, thereby destroy-
ing the cellular structure.5 Antineoplastic drugs are a
heterogeneous group of compounds (such as alkylat-
ing agents, metabolic antagonists, antibiotics, mitotic
spindle inhibitors, hormones etc) able to inhibit tumour
growth by disrupting cell division and actively killing
growing cells. These compounds interact with DNA
inhibiting the activities of topoisomerase I and II6,7 and
inducing double- and single-strand breaks, cross-links
and alkylations.8
Department of Life Sciences and Systems Biology, University of
Turin, Torino, Italy
Corresponding author:
Alfredo Santovito, Department of Life Sciences and Systems
Biology, University of Turin, Via Accademia Albertina n. 13,
10123 Torino, Italy.
Email: alfredo.santovito@unito.it
Human and Experimental Toxicology
201X, Vol XX(X) 1–7
ª The Author(s) 2013
Reprints and permission:
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/0960327113512338
het.sagepub.com
SCEs occur as a consequence of interchanges
between DNA replication products at apparently
homologous chromosomal loci and these exchanges
involve DNA breakage and reunion.9 SCEs are
induced by those agents forming covalent adducts to
DNA or otherwise interfere with DNA metabolism
and repair. CAs reflect damage occurred during the
G1 phase in regions that have not undergone repair
or have evolved to a rearranged element. CAs are
breaks, acentric fragments, rings, dicentrics and inter-
chromosomal exchanges, which are often unstable
aberrations and will lead to cell death during prolif-
eration.10 Generally, SCE analysis represents a more
sensitive test, particularly for S phase-dependent
agents (e.g. alkylating agents), allowing to detect gen-
otoxic effects at much lower concentrations than
those required to induce CAs.11
Hospital workers might be exposed to drugs
throughout their use in health care environments. This
occupational exposure may occur in different ways,
such as inhalation of airborne agents, absorption
through skin contact, ingestion during drug prepara-
tion and/or contact with the patient’s body fluids.12–14
To minimize the risk of occupational exposure,
several guidelines and safety recommendations for
the handling of different drugs were issued.15,16 Nev-
ertheless, despite the adoption of these guidelines in
health care institutions, published reports suggest that
some health care workers do not follow the standards
established by their employers, putting themselves at
risk for mutagenicity.17
In this scenario, the use of biomonitoring processes
among personnel with potential worksite exposure is
of primary interest in biological safety. Some cytoge-
netic studies have proven an increased number of
CAs, SCEs and gene mutations among nurses and
other hospital workers.6,18–21 Nevertheless, other
studies resulted to be ambiguous, probably because
of different exposure conditions and because some
confounder factors, such as smoking habits and/or
alcohol abuse, were not always properly taken into
account.22,23
In the present study, we evaluated the incidence of
CAs and SCEs in a sample of hospital nurses that used
complete protective equipment and that have neither
smoked nor consumed alcohol or drugs at least 2
years before analysis. The aim of the study was to
evaluate the eventual genotoxic damage of nurses
chronically exposed to low doses of different drugs.
As expected, the results of this study might be poten-
tially useful in the implementation of intervention
measures aimed to minimize genotoxic risks and
eliminate or significantly reduce worker exposure.
Methods
Study population
The study included 20 female nurses from 2 analo-
gous departments of 2 different hospitals and 20
female control subjects belonging to the administra-
tive staff and working at the same hospitals without
any work-related exposure to hazardous agents.
Demographic characteristics of the studied groups are
reported in Table 1.
The nurses were exposed to different chemicals:
mainly antibiotics and sporadically cytostatic drugs
(cyclophosphamide, ifosfamide, 5-fluoro-uracil etc),
anaesthetic and sterilizing gases such as ethylene
oxide and formaldehyde. All nurses used complete
protective equipment, according to the Italian guide-
lines and were routinely tested for urinary and blood
drugs concentrations. In our sample, we exclusively
considered individuals who have not smoked nor con-
sumed drugs and have not been subjected to diagnos-
tic examinations for a period of at least 2 years prior to
the analysis. All the subjects were healthy volunteers,
received information about the study and were exten-
sively interviewed by a specialized physician with a
Table 1. Demographic characteristics of the studied groups.
Groups N
Age Exposure years
Mean+ SD Range Mean+ SD Range
Nurses 20 37.350+ 11.775 21–58 11.850 + 7.184 1–28
Department 1 10 33.900+ 11.775 21–50 10.300 + 7.103 1–22
Department 2 10 40.800+ 12.309 23–58 13.400 + 7.291 1–28
Controls 20 39.650+ 5.344 32–53 11.200 + 3.205 7–20
Department 1 10 39200+ 6.512 32–53 11.300 + 3.802 7–20
Department 2 10 40.100+ 4.175 34–47 11.100 + 2.685 7–15
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detailed questionnaire in order to provide important
information for the study. The procedures followed
in this work were in agreement with the ethical stan-
dards of the local responsible committee on human
experimentation and have been performed in accor-
dance with the ethical standards laid down in the
1964 Declaration of Helsinki.
Blood sample collection and cell cultures
Blood samples were obtained by venipuncture (5–10
ml) and collected into heparinized tubes for genotoxi-
city testing. All blood samples were coded, cooled
(4C) and processed within 2 h after collection.
Heparinized venous blood (0.3 ml) was cultured in
25 cm2 flasks in 6 ml RPMI-1640 (Biological Indus-
tries, Israel) supplemented with 20% fetal calf serum,
2% of the mitogenic agent phytohemagglutinin-M
(Difco, 0.2 mlAQ 1 ), L-glutamine (2 mM) and antibiotics
(100 IU/ml penicillin and 100 mg/ml streptomycin).
The cultures were incubated for 48 h for CAs assay
and 72 h for SCEs assay, at 37C in an atmosphere
of 5% carbon dioxide in air. To arrest cells in mitosis,
colchicine (0.25 mg/ml; Sigma, St Louis, Missouri,
USA) was added at a concentration of 0.06 mg/ml dur-
ing the last 2 h of culture. Chromosome preparation
was carried out following standard procedures. Cells
were centrifuged at 1000 r/min, slowly resuspended
in 10 ml of pre-warmed hypotonic solution (0.075
M potassium chloride, pre-warmed to 37C), and
incubated for 15 min in a 37C water bath. The cells
were centrifuged at 1000 r/min again and fixed in cold
methanol:acetic acid (3:1) for 20 min at room tem-
perature. The treatment with the fixative was repeated
three times. Finally, the supernatant was discarded;
and the pellet, dissolved in a minimal volume of fixa-
tive, was seeded on the slides.
CAs assay
Air-dried slides were stained for 20 min with 5%
Giemsa stain (pH 6.8) prepared in a So¨rensen buffer.
For each subject, a total of 200 well-spread meta-
phases were analysed for the following categories of
CAs: chromatid breaks (B0), chromosome breaks
(B00), dicentrics (Dic), acentric fragments (AF), rings
(R) and tri- or tetra-radials (TR). Gaps (a-chromatid
lesions) were not scored as CAs. Cells containing any
type of CAs were scored as cells with aberrations
(CAB).
SCEs assay
To measure SCEs in second-division metaphases,
bromodeoxyuridine (BrdU, 5 mg/ml) was added at
24 h. BrdU closely resembles thymidine and is effi-
ciently incorporated into the elongating DNA strands
during replication. After two cell cycles in BrdU
medium, the two sister chromatids differ in the
amount of BrdU present and the chromatid with more
BrdU is lighter in appearance (‘bleaching’ effect).
For sister chromatid differentiation, the cells were
stained with fluorescence dye Hoechst 33258 (Sigma,
10 mg/ml, 20 min, at room temperature in the dark)
and subsequently irradiated with an 8-W ultraviolet
lamp (254 nm) at a distance of about 20 cm for 30
min. Subsequently, the slides were incubated in
2standard saline concentration for 1 h at 60C and
then stained with 5% Giemsa (Sigma) in the So¨rensen
buffer for 10 min. Microscopic analyses were per-
formed at 1000magnification on a light microscope
(CX40, Olympus, Tokyo, Japan).
In order to determine the number of SCE/cell for
each subject, we scored 50 well-spread second-
division metaphases containing 46 chromosomes.
A total of 100 cells from each donor were scored for
the determination of the replication index (RI) and
calculated according to the following formula:
RI ¼ M1 þ 2M2 þ 3M3ð Þ=N , where M1, M2 and M3
represent the number of cells undergoing first, second
and third mitosis, and N is the total number of scored
metaphases (NSM).
Statistical analysis
Statistical analysis was assessed using the SYSTAT
software statistical package programme (version
10.0, Chicago, Illinois, USA). A non-parametric Wil-
coxon test was used to compare the mean frequencies
of SCEs and CAs between nurses and controls. Mul-
tiple regression analysis was used to evaluate the
influence of age and exposure years on SCEs and CAs
frequencies of both groups. All p values were two-
tailed; and the level of statistical significance was set
at p < 0.05 for all tests.
Results
No significant differences were found between groups
in terms of mean age (p ¼ 0.501) and exposure years
(p ¼ 0.825; Table 1).
Results of the SCE analysis are summarized in
Table 2. Significant differences were found between
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exposed and controls in terms of SCEs/NSM fre-
quency (p < 0.001) but not in terms of RI value
(p¼ 0.845). In either group, no statistical significant
differences were found between departments in
terms of SCEs/NSM (p ¼ 0.721 among nurses and
p¼ 0.508 among controls) and RI (p¼ 0.799 among
nurses and p ¼ 0.646 among controls). Among nurses,
regression analyses indicated that the age and the
exposure years did not influence the amount of SCEs
(p¼ 0.609 and p¼ 0.831, respectively). Vice versa, in
the control group, a positive correlation was found
between SCEs/NSM and age (p ¼ 0.002; Table 4).
Results of the CA analysis are summarized in Table
3. No statistically significant differences were found
between exposed and control subjects in terms of
CAs/NSM (p ¼ 0.236) and CAB/NSM (p ¼ 0.266).
Similar to SCEs results, in either group, no statistical
significant differences were found between depart-
ments in terms of CAs/NSM (p¼ 0.725 among nurses
and p ¼ 0.858 among controls) and CAB/NSM
(p¼ 0.779 among nurses andp¼ 0.858 among controls).
Regression analyses indicated that the age and the
exposure years did not influence the level of the CAs
among both exposed (p ¼ 0.829 and p ¼ 0.821,
respectively) and control (p ¼ 0.708 and p ¼ 0.572,
respectively) groups (Table 4). Finally, no significant
differences were found between the two departments
in terms of SCEs/NSM and CAs/NSM among both
nurses and controls (Tables 2 and 3).
Discussion
Several published studies were focused on the occu-
pational risks of nurses and other hospital workers due
to the handling of several types of drugs. Despite the
improvement of safety protection measures, the con-
tamination via inhalation of drug aerosols and/or acci-
dents during the preparation of potentially genotoxic/
mutagenic drugs cannot be completely excluded
among nurses.24–26 Indeed, transient increases of
SCEs and micronuclei (MNs) in cases of accidental
contamination,23 as well as significantly increased
Table 2. SCEs frequency and RI values in metaphases of lymphocytes from nurses and controls.a
Groups N NSM SCEs SCEs/NSM + SE M1 M2 M3 RI + SE
Nurses 20 1000 6545 6.545+ 0.325b 686 735 579 1.946 + 0.055
Department 1 10 500 3338 6.676+ 0.508 335 372 293 1.958 + 0.082
Department 2 10 500 3207 6.414+ 0.431 351 363 286 1.935 + 0.077
Controls 20 1000 4101 4.101+ 0.371b 651 829 505 1.945 + 0.044
Department 1 10 500 1991 3.982+ 0.566 349 420 218 1.965 + 0.062
Department 2 10 500 2110 4.220+ 0.507 302 409 287 1.925 + 0.066
N: number of individuals sampled; NSM: number of scored metaphases; SCEs: sister chromatid exchanges; SE: standard error; RI:
replication index
aRI¼ (M1 þ 2M2 þ 3M3)/N, whereM1,M2 andM3 represent the number of cells undergoing first second and third mitosis and N is the
total number of metaphase scored.
bp < 0.001.
Table 3. CAs frequency in lymphocytes from nurses and controls.
Groups N
Chromosome Aberrations
NSM B0 B00 Dic AF R TR Total CAs Total CABs
CAs/NSM
(mean + SE)
CAB/NSM
(mean + SE)
Nurses 20 4000 43 31 2 19 2 4 101 99 0.0252 + 0.0030 0.0247 + 0.0030
Department 1 10 2000 24 15 1 10 0 2 52 50 0.0260 + 0.0050 0.0250 + 0.0045
Department 2 10 2000 19 16 1 9 2 2 49 49 0.0245 + 0.0040 0.0245 + 0.0040
Controls 20 4000 47 9 5 18 1 0 80 78 0.0200 + 0.0030 0.0195 + 0.0030
Department 1 10 2000 23 5 2 9 0 0 39 39 0.0195 + 0.0050 0.0195 + 0.0050
Department 2 10 2000 24 4 3 9 1 0 41 39 0.0205 + 0.0050 0.0195 + 0.0050
N: number of individuals sampled; NSM: number of scored metaphases; B0: chromatid breaks; B0 0: chromosome breaks; Dic: dicentric
chromosome; AF: acentric fragments; R: ring; TR: tri- or tetra-radials; CAs: chromosomal aberrations; CAB: cells with aberrations; SE:
standard error.
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rates of SCEs, CAs and MNs in occupationally
exposed nurses, were observed.24,27,28
Although previous published studies have demon-
strated a significant increase of CAs among hospital
workers occupationally exposed to drugs,24,27,29,30
in the present study, no chromosomal damage, in
terms of increase of the CAs and CAB frequencies,
was observed among our nurses sample.
Vice versa, we found the frequency of SCEs has
significantly increased. This finding confirms the
results of previous investigations31,32 about occupa-
tionally exposed nurses, whereas for other hospital
workers, such as pharmacy personnel, this pattern was
not observed.23
Increased frequency of CAs is recognized as a
potential predictor of cancer,33,34 whereas no clear
association has been observed between high SCE fre-
quencies and cancer risk.35,36 Increased levels of
DNA damage are not necessarily associated with the
onset of cancer since the damage actually measured
is a consequence of the equilibrium between damage
infliction and repair. In this scenario, the higher SCEs
rate recorded among occupationally exposed subjects
could be considered as a signal suggesting potential
defects in DNA repair processes.10 Defects in cellular
DNA repair have been linked to genome instability,
heritable cancers, premature ageing syndromes and
neurological diseases.37 Moreover, accumulation of
DNA lesions in repair-defective individuals may
cause cell death, either by progressively depriving the
cell of vital transcripts or through apoptosis.38
Results obtained in this study indicate that age
appears to influence the SCEs rate but not the CAs
frequency among control subjects. This finding is in
agreement with previously reported data on the age-
related incidence of chromosomal damage among
control populations. Indeed, while some authors did
not find an increase of CAs with age,39,40 others
reported a significant correlation between age and
SCEs frequency in peripheral blood lympho-
cytes.41–43 The lack of a similar pattern among the
professionally exposed nurses could be due to a
greater incidence of chromosomal damage among
younger individuals.
Finally, we did not find a correlation between chro-
mosomal damage and duration of exposure, which
may reflect the fact that, during chronic exposure, part
of the chromosomal damage is not detectable in vivo
because of the death of lymphocytes.
Conclusion
Our results suggest that a continuous long-term expo-
sure to low doses of chemicals could result in
increased levels of SCEs among nurses. This data
emphasize the importance of biomonitoring of nurses
and other hospital workers handling drugs.
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Table 4. Multiple regression analysis of confounding factors on SCEs and CAs frequencies in peripheral lymphocytes of
the study groups.
SCEs frequency CAs frequency
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CF: confounding factor; -co: -coefficient; EY: exposure years; CAs: chromosomal aberrations.
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